PG
EBS icon

Pendal Group’s Emergent Biosolutions EBS Stock Holding History

Pendal Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-97,226
Closed -$11.4M – 567
2021
Q1 		$11.4M Buy
97,226
+68,810
+242% +$7.05M 0.11% 93
2020
Q4 		$2.55M Buy
+28,416
New +$2.61M 0.03% 185

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pendal Group's EBS Position: Q2 2021 in Review

Pendal Group sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 97,226 shares — an estimated $11.4M sold.

Pendal Group first reported a position in EBS in Q4 2020 and held it in 2 quarters. The position peaked at $11.4M in Q1 2021. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Pendal Group reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Pendal Group sold 97,226 Emergent Biosolutions shares in Q2 2021, an estimated $11.4M.
  • Pendal Group first reported a position in Emergent Biosolutions in Q4 2020 and held it in 2 quarters.
  • Pendal Group's Emergent Biosolutions position peaked at $11.4M in Q1 2021.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Pendal Group's 13F filing for Q2 2021, filed 28 Jul 2021.